Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of Care

Abstract excerpt

Nothing has changed cancer therapy more in the past 5 to 10 years than the introduction of immune checkpoint inhibitors. In solid tumors, the activity of these agents is commonly linked to the presence of a hypermutated phenotype with the expression of tumor-specific neoantigens at the surface of cancer cells that can serve as targets for T cells. A higher tumor mutation burden can be the result of exogenous,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Colorectal Cancer Treatments and Studies
• Share to Genetic factors in colorectal cancer